anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
501,799. Materials for diagnosing tuberculosis. EVERY, C. E. (Lakeland Foundation) June 18, 1937, Nos. 17056/37 and 5230 /39 (the second Provisional Specification being divided out of the first Provisional Specification). [Class 81 (i)] An agent specific to tuberculosis, which on injection produces a reaction indicative of the disease when present, is prepared by extracting a protein which is characteristic of tuberculosis from the solid unaffected tissue or from the blood fibrin of an animal suffering from the disease and making an approximately neutral or mildly acid solution thereof. The extracting agent may be a dilute acid or alkaline solution, e.g. of hydrochloric acid, or sodium hydroxide. The solid tissue used may be fibrous connective tissue, muscular tissue or bone marrow. In obtaining the agent from fibrin, blood is coagulated, the clot washed free from haemoglobin and serum, hardened with acetone and dried.; the dried fibrin is then pulverized and extracted with decinormal sodium hydroxide, centrifuged, and the liquid rendered neutral or slightly acid by the addition of hydrochloric acid and potassium phosphate, the final pH preferably being 6-9 Tricresol and glycerine is added to the preparation as a preservative. The agent is similarly obtained from muscular tissue by removing blood and fat, drying, pulverizing and extracting.. If tuberculosis is present in a subject, a slight area of inflammation and the formation of pseudopods is observed round the point of injection.
In this feasibility pilot, all participants will be assigned to work with a care manager for 6 months and receive all components of the intervention. The care manager will meet with participants in virtual appointments every month to create a care plan and monitor progress. The program will also include: 6-10 sessions of Cognitive Behavioral Therapy (CBT) for chronic pain, which focuses on skills and strategies to empower participants to better manage their pain. Finally, the Care Manager will help refer patients to Enhance Fitness, an online community program that allows users to access instructor-led group exercise classes from home.
Human biliary tree hepatocytes/progenitors (hbtscs) are being used for cell therapy in patients with cirrhosis. Cryopreservation methods were established to optimize the source of hbtscs for these clinical projects and contained serum-free Kubota Medium (KM) supplemented with 10% dimethyl sulfoxide (DMSO),. -3% recombinant human albumin and 0.1% hyaluronic acid. Cryopreserved hbtscs are similar to freshly isolated hbtscs in vitro in terms of self-replication, stem cell characteristics and pluripotency. They are capable of differentiating into functionalized hepatocytes, cholangiocytes, or islet cells, producing similar secreted levels of albumin or glucose-induced levels of insulin. Cryopreserved hbtscs are equally able to be transplanted into immunocompromised mice as compared to freshly isolated hbtscs, producing human albumin levels in serum of cells and mice with human specific gene expression, with cryopreserved hbtscs having higher human albumin levels than freshly isolated hbtscs. Successful cryopreservation of btscs facilitates the establishment of a pool of btsc cells, providing logistical advantages for clinical programs for treatment of liver diseases.
Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
Methods and systems of patient treatment are disclosed. The methods and systems include use of medical device informatics to modify and validate therapies and drugs used in those therapies. In certain embodiments, a medical device, such as a medical infusion pump, interfaces with a server to administer the patient treatments. In one such embodiment, a method for use of metadata on medical devices is disclosed. A method includes associating metadata with one or more medical devices, the metadata corresponding to an attribute of the medical devices. The method also includes storing the metadata on a server, the server configured to communicate with each of the medical devices by using the metadata.
Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
Most firearm related homicides involve the deceased being forensically examined within a day or two, however, there are times when bodies have been examined and the fired components removed several days or weeks after death, when the body is in an active or advanced state of decomposition. In these cases, ballistic investigation has been found to be complicated due to the damage to the bullets, however the extent of this is not yet known. To date, there have been no studies investigating the effect of human decomposition and the subsequent analysis of bullets lodged in the body in an Australian context. Herein, seven fired copper jacketed bullets were manually inserted into three specific tissue types; lungs, abdomen and leg muscle (twenty-one bullets in total), of human donors in both cool and warm conditions at the Australian Facility for Taphonomic Experimental Research (AFTER). Bullets were removed every three days for a period of twenty-one days, and each bullet underwent manual microscopic examinations by firearms examiners across Australia. Results have indicated that the bullets corrode quickly in warm conditions, compared to bullets exposed to decomposition in cooler conditions. The results of this study will inform investigators and pathologists of the need to remove and examine fired bullets from decomposed bodies as soon as possible, especially in warm conditions to provide firearms examiners with the best opportunity to link fired bullets to a common source.
Patients taking dual antiplatelets (DAT) and who visited for colonoscopy were eligible for enrollment in this study. On enrollment, patients were randomized to two groups. One group continued DAT and the other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy. If polyps (≤1 cm) were observed during colonoscopy, they were removed by cold snare polypectomy. The primary aim was to compared the delayed bleeding rates of the two groups.
A method of preventing necrotizing tissue injury in gastro-intestinal tract comprising orally administering glutamine is described. Glutamine protects tissues along the gastro-intestinal tract by blocking translocation of bacterial agents (such as gram (-) bacteria), other infectious agents, toxins, chemicals, and injurious substances. The intraluminal/apical presence of the glutamine optimizes mucosal defense and increases nutrient absorption. Glutamine may be administered to pre-term or full-term infants, children and adults. Enteral glutamine is useful in treating neonatal necrotizing enterocolitis for reducing inflammation caused by bacterial translocation and injury. Oral glutamine is also useful in treating gastro-intestinal dysfunctions. When glutamine is orally administered it coats gastro-intestinal mucosa thereby treating infectious and/or inflammatory conditions of the gastro-intestinal tract. It is useful in treating pathologic conditions with lowered transepithelial electrical resistance (TEER) by acting as a curative agent. Glutamine may be provided in any form such as powder, capsules, acid-resistant slow-release microcapsules, in a reconstituted liquid or the like. Glutamine may also be orally administered in a mixture. Other drugs for treatment may also be administered with the glutamine. Glutamine is administrable via naso-gastric tube, especially for preterm infants.
Participants received matching placebo orally twice daily (BID) for 6 weeks (Days 1-42) in Stage 1. Participants who completed Stage 1 were eligible to Participate in Stage 2.
OBJECTIVES: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative progressive disease of central nervous system that mostly affects young adults. (1) Because of involvement of spinal cord and brain, lower urinary dysfunction symptoms are commonly encountered. MS patients mostly show overactive bladder symptoms like urgency, frequent daytime urination, and urgency incontinence. Among MS patients, antimuscarinic therapy is the first-line treatment with overactive bladder symptoms as well as in general population yet 30% of the patients show insufficient improvement or intolerance to the treatment (2). In our study, our aim is to evaluate the efficacy and safety of mirabegron add-on treatment in MS patients after inadequate response to antimuscarinic monotherapy.
METHODS: University of Kyrenia and Dr Burhan Nalbantoglu State hospital's databases were screened for the study. Seventy patients who were residents diagnosed with MS according to McDonald criteria were questioned. Among these patients, a total of 22 of them were included in the study. Inclusion criteria was at least 3 years of MS diagnosis, score of <6 at Expanded Disability Status Scale, and a score of ≥3 at Overactive Bladder Symptom Score Scale.
RESULTS: Among selected patients, 10 mg solifenacin treatment was daily started and followed for 4 weeks. Mirabegron add-on treatment was initiated to the 11 patient who had inadequate improvement in overactive bladder symptom score. After mirabegron add-on treatment among 11 patient, there was a sufficient improvement in overactive bladder symptom score ( P < 0.008).
CONCLUSIONS: In our study, we have found that antimuscarinic and mirabegron combination causes improved efficacy for overactive bladder in MS population.
BACKGROUND AND AIM: Lumen-apposing metal stents (LAMS) are preferred to initial drainage in pancreatic fluid collections (PFCs) patients with disconnected pancreatic duct syndrome (DPDS) in recent years. However, unlike plastic stents, the long-term placement of LAMS is not recommended due to a high risk of local complications. This meta-analysis attempted to evaluate the effect of using plastic stents for prolonged drainage after LAMS removal on recurrence of PFCs in DPDS.
METHODS: A comprehensive literature search was conducted from inception until January 2023, to identify articles investigating the endoscopic ultrasound (EUS)-guided treatment of plastic stents compared with no plastic stents following LAMS removal in patients with PFCs and DPDS. The primary outcome measures included recurrence of PFCs and need for reintervention.
RESULTS: We identified 3 eligible articles including 520 patients with PFCs, 246 of whom with DPDS. There was a total of 143 and 103 patients in the plastic stents group and in the no plastic stents group, respectively. The plastic stents group exhibited a lower rate of PFCs recurrence following LAMS removal after PFCs resolution compared with the no plastic stents group (OR 0.15; 95% CI 0.03-0.75; P =0.02). However, there was no difference in the rates of reintervention between the two groups (OR 0.52; 95% CI 0.15-1.83; P =0.31). There was no severe adverse events and mortality associated with stent placement or exchange in all patients.
CONCLUSION: Deployment of plastic stents for long-term drainage after LAMS replacement can decrease the risk of PFCs recurrence in patients with DPDS following resolution, but it does not impact reintervention rates.
The automated proactive healthcare service and payer based patient scheduling system proactively generates communications to patients with the purpose of scheduling medically appropriate, reimbursable healthcare services. The process utilizes a rules based system to identify patients contained in respective healthcare provider's practice management and patient databases. The system will identify patients eligible for certain healthcare services including but not limited to well-care visits, annual check-ups, and immunizations. The data analyzed by the system includes but is not limited to historical healthcare provider-patient service dates, historical payer reimbursement details, patient demographic data, and payer reimbursement/eligibility details. Those patients identified as eligible for healthcare services will be sent an automated interactive communication regarding that healthcare service to facilitate the scheduling process. The communication is automatically generated by the system and can take any known form including but not limited to voice communication, electronic communication and text communication.
Transmission of HIV from an untreated infected mother to her offspring is thought to occur to some infants perinatally and others at parturition. It is possible that administration of an immunogenic vaccine can reduce the vertical transmission of HIV-1 or moderate its course in infected infants. Successful early sensitization to HIV epitopes might succeed in preventing HIV infection. Alternately, the enhancement of HIV-specific immune function might also succeed in modifying HIV replication and affecting disease progression.

Sixty infants are treated in this randomized, double-blind study; 45 infants receive recombinant Canarypox virus, ALVAC-HIV vCP205, and 15 receive placebo. Mothers serve as proxy for their infants. All infants receive a minimum of four immunizations, at Weeks 0 (within 72 hours of birth), 4, 8, and 12. Initially, 24 patients are randomized to receive one of two doses of vCP205 or a saline placebo. When a suitable subunit vaccine is available, the protocol will be amended and 36 additional infants will be randomized to receive vCP205 alone or with a subunit vaccine at Weeks 4 and 8 (or vaccine placebo with or without subunit placebo). \[AS PER AMENDMENT 11/5/97: 18 infants receive ALVAC-HIV vCP205 at one of two doses and 6 receive placebo.\] \[AS PER AMENDMENT 9/9/99: Cohort 1 received vCP205. Cohort 2 received a higher dose of vCP205. Cohort A received vCP205 placebo (saline). Cohorts 1, 2, and A were double-blinded and closed to accrual in March 1999. As of September 1999, infants are randomized to one of four new cohorts. Cohort 3 receives vCP1452 at Weeks 0, 4, 8, and 12. Cohort 4 receives vCP1452 at Weeks 0 and 4, then receives vCP1452 plus AIDSVAX B/E gp120 at Weeks 8 and 12. Cohort B receives vCP1452 placebo at Weeks 0, 4, 8, and 12. Cohort C receives vCP1452 placebo at Weeks 0 and 4, then receives vCP1452 placebo plus AIDSVAX B/E placebo at Weeks 8 and 12. All infants are followed every 2 weeks for the first 14 weeks of life, and then every 6 months until age 2. Cord blood is used to establish autologous B cell lines, and CTL assays are performed to characterize the immune response to HIV. In addition, CD4 count, viral load, and mucosal antibody responses are measured. Immunized infants who are not infected with HIV serve as controls for the immunogenicity of the vaccines in the infected infants.\] \[AS PER AMENDMENT 1/24/00: AIDSVAX B/E has been replaced with AIDSVAX B/B.\]
Ivabradine causes a dose-dependent reduction in heart rate. The size of the effect is dependent on the baseline heart rate (i.e., greater heart rate reduction occurs in patients with higher baseline heart rate). At recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. Analysis of heart rate reduction vs. dose indicates a plateau effect at doses > 20 mg twice daily. In a study of patients with preexisting conduction system disease (first- or second-degree AV block or left or right bundle branch block) requiring electrophysiologic study, IV ivabradine (0.20 mg/kg) administration slowed the overall heart rate by approximately 15 bpm, increased the PR interval (29 msec), and increased the AH interval (27 msec).   
  
Ivabradine does not have negative inotropic effects. Ivabradine increases the uncorrected QT interval with heart rate slowing but does not cause rate-corrected prolongation of QT.
The present invention relates to a method for producing recombined human liver cytokinin (rHPO) and the application for curing serious hepatic diseases, which belongs to the field of a biologic product manufacturing method and the application. On the basis of obtaining hHPO cDNA and successfully building a high-level expression bacterial strain, a whole set of technologies of inducing expression of engineering bacteria, separation and cracking of inclusion bodies and purification and recoverability of protein is established to obtain a pure product of recombined human liver cytokinin. The recombined human liver cytokinin has the biologic characteristics that an isoelectric point is 7.2, and the molecular weight is 15280 daltons. The recombined human liver cytokinin can be used for the primary culture of liver cells and the proliferation of hepatoma carcinoma cells at the outside of a human body. The recombined human liver cytokinin can be used for promoting DNA synthesis of liver cells of a rat in vivo after 1/3 of the liver is cut and CCl4 is damaged, preventing necrosis of liver cells and obviously enhancing survival rate of the rat with liver function failure induced by CCl4. Experiments indicate that rHPO can be possibly the effective medicine for treating serious hepatic diseases in clinic.
PROBLEM TO BE SOLVED: To obtain a new compound having improved water solubility and high antitumor activity. SOLUTION: This taxane derivative is shown by formula I [A is a group of formula II (R<z> is H, etc.), etc.; X is an alkyl, etc.; Y is H, etc.; Ac is acetyl; B is benzoyl; Ph is phenyl] or its salt. The compound of formula I is obtained by a method for treating 10-deacetylbaccatin of formula III as a raw material with a trialkylsilyl chloride in pyridine, acylating the treated substance with an acylating agent (e.g. an acid chloride) in the presence of a base (e.g. n- butyllithium), then reacting the acylated substance with an oxazolidinecarboxylic acid derivative (e.g. N-benzyloxycarbonyl-2,2-dimethyl-4-phenyl- oxazolidinecarboxylic acid), then treating the reaction product with an acid in a solvent (e.g. ethanol), deprotecting the resultant substance, then catalytically reducing the deprotected substance in the presence of palladium carbon and further acylating the reduced substance with an acid halide in the presence of a condensation agent (e.g. a base).
There is no difference from the treatment schedule performed in usual clinical setting except for an additional F-18 FDG PET/CT scan. Detailed plan of ICI treatment and patient management (dose, administration date, treatment period, and follow-up) follows the standard protocol of our institution in this study.
BACKGROUND AND PURPOSE: In contemporary total hip replacement (THR), dislocation is one of the most common complications. At our institution, the cause of an increase in the dislocation rate was recently reported to be reduced head coverage of a newly introduced neutral liner. We therefore aimed to ascertain whether differences exist in articulating head coverage between the various neutral liners used in contemporary THR. A secondary aim was to utilize coverage measurements to develop a new liner coverage classification.
METHODS: The articulating head coverage of 25 modular neutral polyethylene liners used in 6 uncemented cup designs from 4 major manufacturers was evaluated. The measurements were performed in a metrology laboratory and a mathematical model was developed to calculate coverage of the articulating surfaces. Further, 1 "elevated rim" liner and 1 "face changing liner" were included to develop a new liner coverage classification.
RESULTS: The articulating head coverage among the studied liners ranged from 167.7° to 194.8°, corresponding to a variation of 27.1°. The variations with different cup and head sizes within each design were smaller (from 1.0° to 5.6°) than those between different designs. Each of the liner designs offered distinct coverage, even though they were all classified as neutral. Based on measurements, a set of descriptive parameters to discriminate different liners in terms of coverage was created.
CONCLUSION: We showed that all neutral liners are not equal - instead, they clearly varied in terms of their actual coverage design. We suggest our set of descriptive parameters called "hemispheric coverage index values" be used in discriminating the differences in liner coverage.
The best VATS technique for lobectomy has not been well defined yet. Most of the authors describe the VATS approach to lobectomy via 2 to even 4 incisions. The final step in the evolution of the technique is the use of a single-port approach. If conventional multiportal VATS is superior to open thoracotomy by virtue of minimizing surgical access trauma, then further reduction in such access trauma should yield even greater benefits. Therefore, reducing the number of wounds from three or four to just one, should, in theory, lead to less pain, paresthesia, and morbidity as well as faster recovery. However, critics of the uniportal VATS approach may raise concerns about whether this most minimally invasive surgical approach for lung surgery may compromise safety and treatment efficacy. In addition, there's the concern about true invasiveness of the procedure. This prospective, randomized controlled trial was designed to compare the postoperative pain after VATS lobectomy performed through one, two and three incisions. The primary outcome measure is pain intensity measured in VAS scale. The secondary outcome measures are cumulative morphine consumption up to 72 hours after surgery in 4-hour intervals and dynamic spirometry (PEF, FEV1 and FVC) measured daily at the bedside up to 72 hours after surgery. All patients will receive the same regimen of postoperative analgesia based on thoracic epidural block, non-steroidal anti-inflammatory drugs and rescue doses of morphine in PCA system. The side effects and complications including atelectasis, pneumonia, atrial fibrillation, urine retention, hypotension, respiratory depression and sedation will be analysed.